Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nanobiotix ( (NBTX) ) just unveiled an update.
Nanobiotix announced on May 4, 2026 that the U.S. FDA has accepted a protocol amendment, submitted by global study sponsor Johnson & Johnson, to the pivotal Phase 3 NANORAY-312 trial in head and neck cancer evaluating JNJ-1900 (NBTXR3). The amendment removes a planned interim analysis and reduces the number of events required for the final analysis, allowing the primary readout to occur earlier than originally scheduled.
According to Nanobiotix, the streamlined design could accelerate and broaden the global registration path for JNJ-1900 (NBTXR3) in head and neck cancer, potentially pulling forward revenue opportunities and milestone payments tied to its co-development deal with Janssen. The change comes as the nanoparticle-based therapy is being advanced across multiple solid tumors, reinforcing Nanobiotix’s strategic positioning in radiotherapy-activated oncology treatments and its reliance on partners such as Johnson & Johnson and MD Anderson to scale development.
The most recent analyst rating on (NBTX) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The score is held back mainly by weak financial fundamentals—ongoing losses, consistent cash burn, and balance-sheet pressure from negative equity and higher debt. Offsetting this, technicals are relatively strong with an upward trend and positive MACD, while the latest earnings update was constructive on liquidity/runway and clinical progress but tempered by one-off revenue effects and dependency on J&J-controlled timelines.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches to improve treatment outcomes for cancer and other major diseases. Founded in 2003 and headquartered in Paris with a U.S. subsidiary in Cambridge, Mass., the company develops nanotechnology platforms, notably JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle therapy activated by radiotherapy and aimed at multiple solid tumors.
Average Trading Volume: 65,578
Technical Sentiment Signal: Buy
Current Market Cap: $1.5B
Learn more about NBTX stock on TipRanks’ Stock Analysis page.